What Terray Therapeutics does
Terray Therapeutics is an AI-native small-molecule drug discovery company that aims to improve the speed, cost, and success rate of de novo discovery by tightly integrating high-throughput experimentation with computation. The company states that it invents its own hardware, builds its own datasets, and designs its own AI, positioning its platform around iterative “experimentation meets machine intelligence” workflows. Terray’s platform is organized around (1) generating candidate chemistry and experimental measurements at scale, (2) predicting multiple drug-discovery endpoints with proprietary models, and (3) selecting which molecules to synthesize and test next—forming a design–make–test–analyze feedback loop. Terray’s public-facing platform is described as tNova (in earlier materials) and as its newer EMMI (Experimentation Meets Machine Intelligence) platform with EMMI Predict (TerraBind) and other components such as TerraSynth for generative synthesis planning. The company also discloses strategic collaborations and partnered programs, including a multi-target collaboration with Bristol Myers Squibb and other partnerships referenced on its website and in press releases.
Business model: Terray appears to operate as an internal drug discovery pipeline company while also running partnered programs with pharmaceutical companies that use Terray’s platform to discover and optimize small molecules, typically with milestone-based and royalty economics disclosed in partnership announcements. As a result, Terray’s value proposition to partners is less about general-purpose software and more about an experimentation-and-data “flywheel” intended to continuously train and improve models, while also generating purpose-built chemical datasets and supporting synthesis/iteration at short cycle times.
Strategic position (as of the latest company-published updates): Terray has announced a $120M oversubscribed Series B (Oct 17, 2024) and reports rapid progress in its model and workflow components through 2025–2026 releases on its News + Research site, including EMMI Predict: TerraBind and TerraSynth technical content. The company also continues to expand leadership and governance, including board appointments described in press releases.